627P Phase II neoadjuvant trial of the anti–B7-H3 antibody, enoblituzumab, in men with localized prostate cancer: Safety, efficacy and immune correlates

Abstract

Background: Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy (TRT) is a promising investigational therapy for patients with progressive metastatic castration-resistant prostate cancer. PSMA TRT conjugates a radionuclide emitting alpha radiation (e.g., Actinium-225) or beta radiation (e.g., Lutetium-177) to a small abstracts Annals of OncologyVolume 32 -Issue S5 -2021 S663